Insulin resistance and its treatment by thiazolidinediones.
about
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetesAssociation between markers of systemic inflammation, oxidative stress, lipid profiles, and insulin resistance in pregnant womenSynergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempolSimilar causes of various reproductive disorders in early lifePioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia.Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.Enhanced fatty acid flux triggered by adiponectin overexpressionHow free fatty acids inhibit glucose utilization in human skeletal muscle.Novel antihypertensive agents.Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone.Circulating levels of phthalate metabolites are associated with prevalent diabetes in the elderlyTreating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.Disorders of glucose metabolism in the context of human immunodeficiency virus infection.The effects of thiazolidinediones on blood pressure levels - a systematic review.Pharmacogenetics of thiazolidinedione therapy.Thiazolidinediones and diabetic nephropathy: need for a closer examination?Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?Review article: Thiazolidinediones and heart failure.PPAR-γ agonism for cardiovascular and renal protection.Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.Insulin resistance in ischemic stroke.Islet-1: a potentially important role for an islet cell gene in visceral fat.Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat.Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.Treatment options in insulin resistance obesity-related acanthosis nigricans.The long-term effects of rosiglitazone on serum lipid concentrations and body weight.Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice.Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly.Antihyperglycemic effect of polyphenols from Acerola (Malpighia emarginata DC.) fruit.Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
P2860
Q27007027-004D625B-CDEB-4323-A7A0-D7711A61D24DQ28218908-3E8B0EE4-7FBB-4226-9245-3E77F9AB61EAQ28681446-8910B6C8-2284-4A0E-BE2C-A25B9504210FQ34149341-069BB067-FAD7-48E7-8E0A-89E6F54B5B4CQ34394422-1513101A-2D1A-4643-823C-6BF11E1B83C0Q34442391-EF0F4A15-558A-4568-90CE-2B6B266C0C56Q34764949-CFF62EFE-168D-4E7B-95AA-B331223A7BF0Q34835012-B3BCD023-41EC-44B2-B91A-89F8082049EBQ35646093-847B68C8-C834-4710-BE84-569E632F370AQ35773111-DA2E7AE2-9399-4BDB-A5FC-F02141A6DC26Q35842537-B82039A4-6BC1-4BF9-A052-1EF860D839B7Q35989215-AC7EDCA5-F322-4069-A852-AE87EB35F5EEQ36047172-1CFA5030-E4CA-4E99-BA8D-DD53FDE7BF84Q36283822-8E3E32A6-57DB-4601-82A6-7C201DAEAC0EQ36405647-9D326F08-3BC6-4524-88AB-A74472E55DE0Q36545395-AE0463FF-B88F-4F81-B3E3-1B91AE13AEB4Q36918107-DFA7FA36-250A-4527-A988-621625649C9CQ37024419-CBFCC4CA-9C0D-49C7-B78D-9FE6F85F0C91Q37142138-27EDA26A-4E30-413F-8901-4F1C125CB62AQ37470376-A7889034-1ABB-4116-AA0F-3179DBC0E3DAQ37724501-7A75F5B1-81BC-44F3-9C41-E2B8F204D930Q37788729-48D1FAFB-7A9C-41E3-ABC9-38D6FE7ACC6AQ37992099-CB8E6B88-D795-4A6F-82F1-1048333D9D5EQ39387402-E6A7FDED-A4CC-457D-942B-BC52F2112118Q42817394-D51F6904-3BED-4A99-A6BA-8A981953FE52Q43109238-96ED5D02-0617-43C9-92F1-1CCE8DF782E8Q44474584-A248C97B-0EC7-4A39-A322-B13F554E8A65Q44613028-A351461A-C8A2-4B2A-856A-7454AF85E1DDQ46156535-131577B3-B267-429D-8914-D7A7CA38ADAAQ47321113-3B980949-00C5-4AF0-B690-61853BE27985Q47998214-75CF6E9F-8612-4F27-8B43-58DF48353D54Q51330045-F8597812-81EB-420F-BEA2-F4049919E6BFQ53603710-685C20BF-D739-4230-A314-93A99B6801BAQ55434689-40DAE689-F7FA-4368-960B-A04B1C611045
P2860
Insulin resistance and its treatment by thiazolidinediones.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Insulin resistance and its treatment by thiazolidinediones.
@ast
Insulin resistance and its treatment by thiazolidinediones.
@en
type
label
Insulin resistance and its treatment by thiazolidinediones.
@ast
Insulin resistance and its treatment by thiazolidinediones.
@en
prefLabel
Insulin resistance and its treatment by thiazolidinediones.
@ast
Insulin resistance and its treatment by thiazolidinediones.
@en
P356
P1433
P1476
Insulin resistance and its treatment by thiazolidinediones.
@en
P2093
H E Lebovitz
M A Banerji
P304
P356
10.1210/RP.56.1.265
P577
2001-01-01T00:00:00Z